NCT01055821已完成2 期
A Phase II Randomized, Multicenter, Open-label Study of TG4040 (MVA-HCV) in Combination With Pegylated Interferon Alfa-2a and Ribavirin Versus Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naïve Patients With Chronic Genotype 1 Hepatitis C.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Transgene
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- complete early virologic response
研究概览
简要总结
The primary objective of this protocol is to study the effect of the standard of care in hepatitis C (pegylated interferon and ribavirin) associated with therapeutic vaccine TG4040 on the viral load of treatment-naïve patients with chronic genotype 1 hepatitis C infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronically infected patients with Hepatitis C virus Genotype 1 (1a or 1b) with detectable viremia (HCV RNA in blood) for more than 6 months and naïve to treatment;
- •Patients must have compensated liver disease, with no history of ascites, jaundice, hepatic encephalopathy or bleeding from esophageal or gastric varices requiring beta-blockers;
- •No histological evidence of hepatic cirrhosis (including compensated cirrhosis) based on a liver biopsy taken within 24 months prior to baseline; or on a FibroScan® performed within 6 months prior to treatment which indicates the absence of liver cirrhosis, i.e., stage < F4 (METAVIR); in case of no available results, a liver biopsy will be performed prior to treatment;
- •All laboratory parameters must be grade 0 or 1 (as per CTCAE criteria) except for alanine amino-transferase (ALT), aspartate amino-transferase (AST), gamma glutamyl transferase (GGT) and alkaline phosphatase (ALP) for which a grade 2 will be allowed if stated non clinically significant;
- •No co-infection with Human Immunodeficiency Virus (HIV) or hepatitis B virus (HBsAg positive);
- •No intravenous (IV) drug or alcohol abuse;
- •Serum thyroid stimulating hormone (TSH) levels within normal ranges, regardless of treatment with L-thyroxin;
- •Normal electrocardiogram (ECG);
- •Normal retinal examination (eye fundus) within last 12 months for diabetic patients or patients suffering from high blood pressure;
- •Negative pregnancy test in women of childbearing potential (a woman who is two years post-menopausal or surgically sterile is not considered to be of childbearing potential);
- •Female patients and female partners of male patients (if childbearing potency) must agree to use two effective methods of birth control during the study and for 6 months after the end of treatment. One of the methods needs to be a 'barrier' method (condom or diaphragm);
排除标准
- •Prior treatment for hepatitis C;
- •Malignancy within the last 5 years; except for patients with history of squamous cell skin cancer or basal cell skin cancer who will be enrolled, unless patients have a history of skin cancer at the vaccination site;
- •Diagnosed or suspected hepatocellular carcinoma;
- •History of psychiatric conditions including, but not limited to, psychosis, suicidal ideations, or major depression. Patients with mild to moderate depression in the past and no prior history of suicidal gestures or attempts may be enrolled if, in the Investigator's opinion, they are suitable for treatment;
- •Serious, concomitant medical disorder, including active systemic infection and proven or suspected immunosuppressive disorder;
- •History of immunodeficiency or autoimmune disease including autoimmune hepatitis, allogenic transplant, or pre-existing autoimmune or antibody-mediated disease including, but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, or autoimmune thrombocytopenia;
- •Administration of any vaccine or immunoglobulin within 30 days before the first dose of TG4040 /SOC;
- •Significant cardiovascular disease (e.g., New York Heart Association [NYHA] class 3 congestive heart failure; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty within the past 6 months; or uncontrolled arterial or ventricular cardiac arrhythmias);
- •Systemic corticosteroid therapy or other immunosuppressive/immunomodulating drugs (e.g. Cyclosporine) within 2 months prior to first TG4040/SOC administration; corticosteroid nasal sprays, inhaled steroids for asthma and/or topical steroids are allowed;
- •Any known allergy to interferon (IFN), RBV and/or their excipients;
- •Any medical contraindications to IFN and/or RBV;
- •Any known allergy to eggs;
- •Women who are breastfeeding;
研究组 & 干预措施
Arm A
Active Comparator
Standard of care (SOC)
干预措施: pegylated interferon and ribavirin (Drug)
Arm B
Experimental
Vaccine and Standard of care
干预措施: TG4040 + SOC (Biological)
Arm C
Experimental
vaccine and standard of care
干预措施: TG4040 + SOC (Biological)
结局指标
主要结局
complete early virologic response
时间窗: 12 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)Hepatitis C, ChronicNCT00953589Biolex Therapeutics, Inc.74
已完成
1 期
Staged Phase I/II Hepatitis C Prophylactic VaccineHepatitis CNCT01436357National Institute of Allergy and Infectious Diseases (NIAID)548
招募中
2 期
A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis BChronic Hep BHBVHepatitis BNCT04568265Ascentage Pharma Group Inc.122
已完成
1 期
Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis CChronic Hepatitis CNCT00120835Merck Sharp & Dohme LLC
已完成
2 期
Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIVHIVHepatitis CNCT01878799National Institute of Allergy and Infectious Diseases (NIAID)50